Rebranded Rezera plans IPO to fund phase 3 trial of NLRP3 inhibitor ruvonoflast for peripheral artery disease

Rezera, which rebranded from NodThera last month, announced plans for an initial public offering to raise capital for its lead candidate, ruvonoflast, a brain‑penetrant NLRP3 inhibitor.

The company says the IPO proceeds will be directed mainly toward a phase 3 study in peripheral artery disease slated for next year and to ready the business for a potential commercial launch.

Earlier this month, Rezera released phase 2 results showing that a combination of ruvonoflast with semaglutide lowered high‑sensitivity C‑reactive protein more than semaglutide alone, indicating an anti‑inflammatory effect.

The SEC filing did not disclose the number of shares to be offered or the pricing, but the biotech remains focused on advancing ruvonoflast toward regulatory approval.